Use of mometasone furoate for treating airway passage and lung disease

Abstract

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

1 - 29 . (canceled)  
   
   
       30 . A method of treating a corticosteroid-responsive disease of the upper airway passages comprising administering once daily to nasal passages about 200 micrograms of mometasone furoate:  
   
   
       31 . The method of  claim 30 , wherein the mometasone furoate is administered as anhydrous mometasone furoate.  
   
   
       32 . The method of  claim 30 , wherein the mometasone furoate is administered as mometasone furoate monohydrate.  
   
   
       33 . The method of  claim 30 , wherein the mometasone furoate is administered in the form of an aqueous suspension.  
   
   
       34 . The method of  claim 30 , wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate.  
   
   
       35 . The method of  claim 30 , wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate.  
   
   
       36 . The method of  claim 30 , wherein there are administered 200 micrograms of mometasone furoate by applying two times to each nostril about 50 micrograms of mometasone furoate.  
   
   
       37 . The method of  claim 34 , wherein the aqueous suspension is unscented.  
   
   
       38 . The method of  claim 30 , wherein the corticosteroid responsive disease is selected from the group consisting of seasonal allergic rhinitis, perennial rhinitis, seasonal or perennial sneezing, rhinorrhea, nasal congestion, non-malignant proliferative disease of the airway passage, pruritis, eye itching, redness, tearing, and non-allergic rhinitis, and/or the prophylaxis thereof of any of the aforementioned diseases.  
   
   
       39 . The method of  claim 38 , wherein the disease is a non-malignant proliferative disease of the airway passage.  
   
   
       40 . A method of treating a corticosteroid-responsive disease of the upper airway passages comprising administering twice daily to nasal passages about 200 micrograms of mometasone furoate.  
   
   
       41 . The method of  claim 40 , wherein the mometasone furoate is administered as anhydrous mometasone furoate.  
   
   
       42 . The method of  claim 40 , wherein the mometasone furoate is administered as mometasone furoate monohydrate.  
   
   
       43 . The method of  claim 40 , wherein the mometasone furoate is administered in the form of an aqueous suspension.  
   
   
       44 . The method of  claim 40 , wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate.  
   
   
       45 . The method of  claim 40 , wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate.  
   
   
       46 . The method of  claim 40 , wherein there are administered 200 micrograms of mometasone furoate by applying two times to each nostril about 50 micrograms of mometasone furoate.  
   
   
       47 . The method of  claim 40 , wherein the aqueous suspension is unscented.  
   
   
       48 . The method of  claim 40 , wherein the corticosteroid responsive disease is selected from the group consisting of seasonal allergic rhinitis, perennial rhinitis, seasonal or perennial sneezing, rhinorrhea, nasal congestion, a non-malignant proliferative disease of the airway passage, pruritis, eye itching, redness, tearing, and non-allergic rhinitis, and/or the prophylaxis thereof of any of the aforementioned diseases.  
   
   
       49 . The method of  claim 38 , wherein the disease is a non-malignant proliferative disease of the airway passage.